← Back to all trials
Recruiting
NCT07013591
Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
Conditions: Coronary Artery Bypass Graft
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 90
Sponsor: Brigham and Women's Hospital
Location: Brigham and Women's Hospital Boston Massachusetts
Summary
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years
2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
3. At increased risk of postoperative complications based on ≥1 of the following:
1. Age ≥65 years
2. eGFR \30 mg/g creatinine
5. Peripheral arterial disease
6. Anemia, defined as hemoglobin \3-fold the upper limit of normal
2. eGFR \
Source: ClinicalTrials.gov (NCT07013591). StuddyBuddy aggregates publicly available trial information.
